GLP-1s are reducing appetites, which means consumers are seeking extra functionality in the food they buy. At the forefront of that functionality is fiber. For many taking these medications, fiber intake is a real concern. Stand out by being the brand that makes managing it easy. Source: https://lnkd.in/g3CAksdi
GLP-1 Medications: The Rise of Fiber-Rich Foods
This title was summarized by AI from the post below.
More Relevant Posts
-
That's the way the cookie crumbles: The profiteering food industry, time for a reckoning. I find the recent Jefferies report on the "structural threat" of GLP-1 drugs to the food industry deeply revealing. It is a "mask-off" moment for our obesogenic society. The report identifies a specific group as the primary risk to profits: "Heavy Users." In the cold language of investment banking, these are the "most valuable" customers. But let’s call it what it actually is: this "value" is extracted from individuals trapped in a state of metabolic chaos. Our economy has become functionally dependent on people’s inability to feel full. For decades, billion-dollar industries that have thrived on bypassing human satiety. A "valuable" customer, in this twisted logic, is someone whose internal biological signals have been silenced by ultra-processed engineering, leading to a cycle of high-volume, low-value consumption. But the "Ozempic Effect" is changing the physics of the market. The fact that analysts view "public health" as a "structural headwind" confirms the uncomfortable truth: a massive sector of our economy has been predicated on maintaining human disorder. When patients regain their internal clarity, they no longer seek the empty calories that have sustained these balance sheets for years. The lesson for the industry is stark: if your profit model requires your customers to remain "Heavy Users" of metabolic dysfunction, you aren't facing a trend—you are facing a reckoning. The future belongs to those who provide actual nourishment, not those who thrive on the exploitation of a broken biological signal.
The Ozempic effect just came for the sausage roll... If you thought the GLP-1 wave was just a challenge in the US, look at Greggs. Analysts at investment bank Jefferies have just downgraded the UK chain, citing weight-loss drugs as a "structural issue" for the business. Their logic is brutal but clear: they estimate nearly 4 million people in the UK (7.5% of adults) could be using these drugs. While that might not seem like a lot, the analysts flagged the critical 'Heavy User' dynamic: "It may only be 10% of GLP-1 users that would shop at Greggs. But that 10 per cent would be high-BMI individuals, consuming lots of calories and, we would infer, likely some of Greggs’s best customers. Those customers go from being among Greggs’s most-valued to potentially never spending a penny with the business again." This is the Pareto Principle in reverse. Most food brands rely on a small percentage of 'super-consumers' for a large chunk of their volume. Jefferies reckon these are the very people who are most likely to be turning GLP-1s. Greggs CEO Roisin Currie has admitted there is “no doubt” the drugs are having an effect, pivoting the menu toward healthier options like egg pots. The lesson? Adapt or decline. Now your most loyal customers are being biologically deactivated you need to pivot your growth strategy. 'Calorie Volume' is out, 'Calorie Value' is in. #insight #humanfirst #glp-1
-
-
Many GLP‑1 medications are available today under different brand names, and one of the most common things we hear from members is: “I don’t want to be on this medication for the rest of my life.” Our continuous glucose monitoring (CGM) approach helps optimize how these medications are used so members can achieve the best possible outcomes. https://lnkd.in/gfqbhaT2 #level2 #cgm #type2improved Dave Moen, MD
-
-
We ran a short pulse survey amongst people using GLP-1 for weight loss to understand how their spending habits and consumer choices were impacted as a result of their GLP-1 use. This has landed the week the Independent ran a story about the fast food industry is having to adapt to the needs of this user group who need nutrient dense smaller portions. Really interesting 'takeaways' from this - a clear move to quality is flagged through the qualitative findings. Take a read through our report.
GLP-1 is part of everyday life for around 1.6 million people across the UK, and that number is steadily growing. But the impact of GLP-1 isn’t limited to appetite alone. We’ve just published a new report exploring how people taking GLP-1 medications say their everyday choices are evolving, from food and spending to habits and priorities. The patterns emerging point to meaningful behavioural shifts with clear commercial implications for organisations in food, drink, retail and health. Understanding this change now will shape where future growth opportunities sit. You can download the full report here: https://lnkd.in/e3AQGrKh
-
-
With around 1.6 million people (and rising) in the UK alone now taking GLP-1 medications, brands and manufacturers are quickly having to think about what it means for them. As usage grows, so too will the ripple effects. The brands that adapt to evolving needs and expectations will stay relevant and those that don’t risk being left behind. To me it feels like we are only at the very tip of the iceberg for how GLP-1 could reshape human spending habits and behaviours and become a mainstream medication for millions of people around the world, with widespread commercial consequences for many
GLP-1 is part of everyday life for around 1.6 million people across the UK, and that number is steadily growing. But the impact of GLP-1 isn’t limited to appetite alone. We’ve just published a new report exploring how people taking GLP-1 medications say their everyday choices are evolving, from food and spending to habits and priorities. The patterns emerging point to meaningful behavioural shifts with clear commercial implications for organisations in food, drink, retail and health. Understanding this change now will shape where future growth opportunities sit. You can download the full report here: https://lnkd.in/e3AQGrKh
-
-
We’re pleased to share Acumen’s latest report exploring how people taking GLP-1s describe changes to their everyday choices, from food and spending to lifestyle priorities. The findings highlight the wider behavioural ripple effects of treatment, offering insight that’s relevant for healthcare providers, patient support programmes and brands operating in this space. Take a look at the full report here: https://lnkd.in/e3AQGrKh https://lnkd.in/eAK3wfeE
GLP-1 is part of everyday life for around 1.6 million people across the UK, and that number is steadily growing. But the impact of GLP-1 isn’t limited to appetite alone. We’ve just published a new report exploring how people taking GLP-1 medications say their everyday choices are evolving, from food and spending to habits and priorities. The patterns emerging point to meaningful behavioural shifts with clear commercial implications for organisations in food, drink, retail and health. Understanding this change now will shape where future growth opportunities sit. You can download the full report here: https://lnkd.in/e3AQGrKh
-
-
It’s been a little while since I’ve shared anything on here but lots of good things have been happening behind the scenes. One of them is this report we’ve recently published exploring how GLP-1 is influencing everyday life in the UK. What stood out to me isn’t just the scale (1.6 million people and growing), but the broader behavioural ripple effects from food choices to spending habits and priorities. It’s a reminder that shifts in health behaviours don’t happen in isolation. Proud to be part of work that looks beyond the headline and digs into what change really means.
GLP-1 is part of everyday life for around 1.6 million people across the UK, and that number is steadily growing. But the impact of GLP-1 isn’t limited to appetite alone. We’ve just published a new report exploring how people taking GLP-1 medications say their everyday choices are evolving, from food and spending to habits and priorities. The patterns emerging point to meaningful behavioural shifts with clear commercial implications for organisations in food, drink, retail and health. Understanding this change now will shape where future growth opportunities sit. You can download the full report here: https://lnkd.in/e3AQGrKh
-
-
GLP-1 is part of everyday life for around 1.6 million people across the UK, and that number is steadily growing. But the impact of GLP-1 isn’t limited to appetite alone. We’ve just published a new report exploring how people taking GLP-1 medications say their everyday choices are evolving, from food and spending to habits and priorities. The patterns emerging point to meaningful behavioural shifts with clear commercial implications for organisations in food, drink, retail and health. Understanding this change now will shape where future growth opportunities sit. You can download the full report here: https://lnkd.in/e3AQGrKh
-
-
Temperature control requires precision – not guesswork.❄️🚛 In temperature-controlled transportation, even a small deviation can impact product quality, safety, and compliance. From food and pharmaceuticals to cosmetics and chemicals, stability is what protects everything downstream. Our latest guide breaks down the realities of temperature control - where risks start, why planning matters, and how the right approach safeguards your freight. 👉 Read the full article here: https://lnkd.in/e6rDJ4hm #ColdChainLogistics #TemperatureControlled #SupplyChainInsights
-
Interesting paper from Healy Group on rising impact of GLP-1 I'm working with Millbo srl at the moment, who produce Panvivo GLP1ve, one of the products called out in the report and available via Healy. A new generation concentrate, that is helping bread manufacturers create products that support those on GLP, or coming off the drugs The GLP trend is not just impacting those taking the jabs. It is also influencing others who want nutrient dense foods, eating less with more impact.
The rise of GLP-1 medications is no longer just a healthcare story - it’s a transformation for the food industry. I know first hand how frustrating it can be to see a new trend or hear a buzzword but when seeking information, everything you come across is regurgitated information that you've already seen. No action plans, solutions or a way forward. Because of this, we have decided to cut through the noise of GLP-1 and turn it into something tangible and useful for NPD teams and buyers alike in the form of a technical paper. If you want a sneak preview of the paper that I have written, before this goes live, then please click on the link below https://lnkd.in/e867-zZN
-
-
The rise of GLP-1 medications is no longer just a healthcare story - it’s a transformation for the food industry. I know first hand how frustrating it can be to see a new trend or hear a buzzword but when seeking information, everything you come across is regurgitated information that you've already seen. No action plans, solutions or a way forward. Because of this, we have decided to cut through the noise of GLP-1 and turn it into something tangible and useful for NPD teams and buyers alike in the form of a technical paper. If you want a sneak preview of the paper that I have written, before this goes live, then please click on the link below https://lnkd.in/e867-zZN
-
Hello Steve, You may explore this one www.fenutein.com